1290546-22-3Relevant academic research and scientific papers
Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist
Xue, Chu-Biao,Feng, Hao,Cao, Ganfeng,Huang, Taisheng,Glenn, Joseph,Anand, Rajan,Meloni, David,Zhang, Ke,Kong, Lingquan,Wang, Anlai,Zhang, Yingxin,Zheng, Changsheng,Xia, Michael,Chen, Lihua,Tanaka, Hiroyuki,Han, Qi,Robinson,Modi, Dilip,Storace, Lou,Shao, Lixin,Sharief, Vaqar,Li, Mei,Galya, Laurine G.,Covington, Maryanne,Scherle, Peggy,Diamond, Sharon,Emm, Tom,Yeleswaram, Swamy,Contel, Nancy,Vaddi, Kris,Newton, Robert,Hollis, Greg,Friedman, Steven,Metcalf, Brian
, p. 450 - 454 (2011/08/22)
We report the identification of 13 (INCB3284) as a potent human CCR2 (hCCR2) antagonist. INCB3284 exhibited an IC50 of 3.7 nM in antagonism of monocyte chemoattractant protein-1 binding to hCCR2, an IC 50 of 4.7 nM in antagonism of c
